Guardian Pharmacy Services (GRDN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
26 Mar, 2026Executive summary
Annual meeting scheduled for May 5, 2026, with materials available online and by request.
Stockholders of record as of March 13, 2026, are eligible to vote on key proposals.
Voting matters and shareholder proposals
Election of two Class II directors to serve until the 2029 annual meeting.
Advisory vote to approve executive compensation.
Advisory vote on the frequency of future say-on-pay votes, with board recommending 1 year.
Ratification of Ernst & Young LLP as independent auditor for 2026.
Board of directors and corporate governance
Board recommends voting for all director nominees and for all proposals except the frequency of say-on-pay, where 1 year is recommended.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Guardian Pharmacy Services
- Q2 2026 net income rose to $22.1M on 2.2% revenue growth and an $8.5M settlement.GRDN
Q2 2026 - Tech-enabled growth and legislative advocacy position the company for continued market expansion.GRDN
Stephens 26th Annual Investment Conference | NASH2024 - Strong growth, stable margins, and expanding market share position the company for continued success.GRDN
Raymond James & Associates’ 46th Annual Institutional Investors Conference - Strong quarter, raised guidance, and poised for growth in the fragmented assisted living pharmacy market.GRDN
Bank of America Global Healthcare Conference 2026 - 13% ALF market share, $1.45B revenue, and tech-driven growth deliver strong outcomes.GRDN
Investor presentation - Q1 2026 revenue and net income rose, prompting higher full-year EBITDA guidance.GRDN
Q1 2026 - Capturing 13% of the ALF pharmacy market, growth is driven by tech, service, and disciplined expansion.GRDN
44th Annual J.P. Morgan Healthcare Conference - Expanding assisted living pharmacy services through tech, analytics, and strategic acquisitions.GRDN
Stephens Annual Investment Conference - Strong 2024 growth and expansion, with 2025 outlook positive despite IPO-related net loss.GRDN
Q4 2024